Mahima Datla is an Indian businesswoman, the self-made billionaire Managing Director (MD) of Biological E. Limited (BE), a major Indian pharmaceutical and vaccine manufacturer. Her wealth is generational, tied to the industrial empire founded by her grandfather, Dr. D.V.K. Raju, in 1953.

Datla graduated from Purdue University with a B.S. in Management. Her career is defined by generational stewardship and executive leadership in the biotechnology and vaccine sector. Her structural role is tied to scaling vaccine manufacturing and public health contributions (providing affordable vaccines globally).

• Biological E. Limited (MD): The core private asset, a major manufacturer of pharmaceuticals and vaccines (a key global supplier of affordable vaccines).
• Biotech Focus: Her success is built on scale manufacturing and R&D in vaccinology and generic drugs (e.g., COVID-19 vaccine production).
• Academic Background: She holds a B.S. in Management from Purdue University.
• Philanthropy: She is actively involved in philanthropic endeavors that support public health and community welfare in India.

Mahima Datla's strategic leadership transformed Biological E. Limited (BE) into a global force. She became MD (and later CEO) and drove the company's aggressive expansion into vaccine manufacturing, securing major contracts with organizations like UNICEF and the World Health Organization (WHO). Her structural contribution is immense: providing affordable, high-quality vaccines to developing nations, which is critical for global public health.

Her company was a major partner in COVID-19 vaccine production (e.g., Johnson & Johnson and the company's own Corbevax), a pivotal global public health role. Her wealth is secured by the colossal, long-term, stable profitability of the global vaccine and generic drug sector.

Mahima Datla's social impact is massive and humanitarian, tied to Biological E. Limited's role in providing essential, affordable vaccines to global populations, significantly contributing to disease prevention (a major structural public health service). Her company was a key player in the global COVID-19 response.

Her personal philanthropy supports various community and educational initiatives. Her structural contribution is tied to the successful generational transition and scale of a critical Indian pharmaceutical asset.

Mahima Datla maintains the professional, composed style of a corporate executive. Her attire is consistently formal and high-quality, favoring tailored suits or traditional Indian business attire. Her aesthetic reflects serious authority and stability, typical of a leader in the specialized biotechnology sector.

Residing in Hyderabad, India, her luxury is the immense security and financial reward derived from her multi-billion dollar fortune. Her life is dedicated to biotechnology innovation, public health service, and the long-term, stable growth of the vaccine supply chain.